Market Mover: IRIDEX (IRIX) Up at Midday August 5

Equities Staff  |

IRIDEX Corp. (NASDAQ: IRIX) has climbed $0.21 (6.82%) and is currently sitting at $3.29, as of 10:42:57 est on August 5.

1,042 shares have been traded today.

The Company has risen 2.31% over the last 5 days and shares advanced 16.54% over the last 30 days.

IRIDEX is set to release earnings on 2022-08-15.

For technical charts, analysis, and more on IRIDEX visit the company profile.

About IRIDEX Corp.

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.

To get more information on IRIDEX Corp. and to follow the company's latest updates, you can visit the company's profile page here: IRIDEX Corp.'s Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content